Psyence BioMed to Engage U.S. Stakeholders on GMP Ibogaine Manufacturing
Event summary
- Psyence BioMed's executive team will travel to the U.S. to meet with researchers, institutions, and government stakeholders on ibogaine research and manufacturing.
- CEO Jody Aufrichtig has submitted a formal letter to President Donald J. Trump and HHS Secretary Robert F. Kennedy Jr. applauding U.S. policy developments supporting psychedelic medicine research.
- Psyence BioMed operates a GMP-compliant facility in Southern Africa for ibogaine production, positioning itself as a key player in the global ibogaine supply ecosystem.
- The company has experienced increased engagement from U.S.-based researchers seeking compliant ibogaine manufacturing capabilities and supply availability.
The big picture
Psyence BioMed's strategic engagement initiative comes at a time of growing interest in psychedelic medicine, particularly ibogaine, for treating serious mental health conditions. The company's vertically integrated model and GMP-compliant manufacturing capabilities position it uniquely to support the emerging global ibogaine supply ecosystem. Recent U.S. policy developments are likely to further expand research opportunities and regulatory pathways for psychedelic compounds, benefiting companies like Psyence BioMed that are well-positioned to meet the demand for compliant manufacturing and supply.
What we're watching
- Regulatory Tailwinds
- How U.S. policy developments will accelerate ibogaine research and manufacturing collaboration.
- Supply Chain Dynamics
- Whether Psyence BioMed can sustain its position as a leading GMP ibogaine supplier amid increasing demand.
- Market Adoption
- The pace at which U.S. institutions adopt ibogaine for clinical research and therapeutic applications.
Related topics